Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 28329350.
- Also identified by DOI 10.1093/cid/cix014 and PMC identifier 5850333.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.
Medical subject headings
- Anti-Bacterial Agents
- Carbapenems
- Cephalosporins
- Penicillanic Acid
- Pseudomonas Infections
- Pseudomonas aeruginosa